| Hazard Information | Back Directory | [Uses]
Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer[1][2][3]. | [in vivo]
Zalutumumab (5 mg/kg; i.p. 2 h after tumor induction) affects tumor growth in A431 xenograft models[3].
Zalutumumab (0.5 and 5 mg/kg; i.p. once ) delays tumor growth when mice with tumor volumes of 80-100 mm3[3]. | Animal Model: | SCID mice with A431 cells injection[3] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection; 5 mg/kg 2 hours after tumor induction | | Result: | Effectively inhibited tumor growth in A431 xenograft models with an early treatment. |
| [References]
[1] Schick U, et al. Zalutumumab in head and neck cancer. Expert Opin Biol Ther. 2012 Jan;12(1):119-25. DOI:10.1517/14712598.2012.643864
[2] Lammerts van Bueren JJ, et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6109-14. DOI:10.1073/pnas.0709477105
[3] Overdijk MB, et al. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol. 2011 Sep 15;187(6):3383-90. DOI:10.4049/jimmunol.1003926 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
|